FL, MZL, and MCL Flashcards

1
Q

Immunophenotype of Follicular lymphoma

A

CD10+ CD20+ BCL2+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Characteristic translocation of FL?

A

t(14;18)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the difference in treatment of FL3A and FL3B

A

3B is treated like DLBCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are components of the FLIPI (5)

A

4+ nodal sites
LDH above ULN
Age >60
Stage III-IV
Hemoglobin <12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does the addition of X to lymphoma stage mean?

A

Bulky disease (>10 cm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When to treat newly diagnosed FL?

A

Essentially symptomatic patients or those with consequences like cytopenias, elevated LDH
Nodes >3cm in 3 areas, LNs or tumor >7 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Treatment for Stage I/II FL?

A

IFRT 24 Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the effect of treating asymptomatic patients with advanced FL with Rituximab?

A

Improves PFS but not OS
This is why observation is an option

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the effect of maintenance Rituximab in advanced FL for those initially treated with Ritux x4?

A

Improves PFS but no difference in OS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the preferred treatment for symptomatic advanced FL? (2)

A

Benda + Rituximab (better PFS than R-CHOP)
Ritux + Len

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MoA of Tazemetostat

A

EZH2 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Approved BiTEs for 3L FL? (2)

A

Mosenetuzumab
Epcoritimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Approved CAR-T for R/R FL? (2)

A

Axicabtagene ciloleucel
Tisagenlucleucel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Immunophenotype fo Marginal Zone Lymphoma

A

CD5- CD10- CD23- BCL6- CyclinD1-
CD19+ CD20+ CD79a+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are common etiologies of extranodal marginal zone lymphoma?

A

Antigen-drive disease. Often GI infections (especially MALT lymphoma)
H pylori,. Campylobacter, Borrelia, Chlamydia psittaci, hashimoto thyroiditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What feature of gastric extranodal marginal zone lymphoma predicts for resistance to H pylori eradication?

A

t(11;18)

17
Q

You have a patient with gastric ENMZL and treat with H pylori eradication. When to repeat endoscopy/biopsy?

A

at least 3 months

18
Q

R/R MZL treatment options (2)

A

Ibrutinib
Zanubrutinib

19
Q

Classic translocation in Mantle cell lymphoma?

A

t(11;14)

20
Q

Immunophenotype of Mantle cell lymphoma

A

CD5+. CD19+, CD20+, Cyclin D1+, FMC7+, SOX11+
CD23-

21
Q

Induction treatment for young/fit patient with mantle cell lymphoma? (3)

A

R-HyperCVAD
R-CHOP
Nordic regimen (R-maxiCHOP/R-AraC)

22
Q

Induction Treatment for older/unfit patient with mantle cell lymphoma

A

BR
R CHOP
Len-R

23
Q

Treatment options for R/R Mantle cell (6)

A

Acala
Zanubritinib
Pirtobrutinib
Ritux - Len
Venetoclax
CAR-T

24
Q

What therapy can be done after autoSCT to improve survival in patients with Mantle cell?

A

Maintenance RItux for 3 years

25
Q

Treatment of splenic MZL?

A

Rituximab
Can offer splenectomy to some

26
Q

Patient with splenic MZL also has active HCV and is symptomatic from lymphoma. Treatment?

A

Treat the HCV - good chance of regression. If it doesn’t then can try Ritux

27
Q

4 less intensive induction treatment regimens for MCL?

A

BR
RCHOP
R - Len
R- Acal

28
Q

Preferred second line treatment for MCL? (2)

A

Acal
Zanubritinib

29
Q

Preferred treatment for primary effusion lymphoma? (2)

A

R-EPOCH
R-CHOP

30
Q

Who should you not give Bendamustine + Ritux (or obina) to in the 2L setting FL?

A

Those that got prior Benda

31
Q

2L options for fit patients with R/R FL? (4)

A

BR or BO
RCHOP or OCHOP
RCVP or OCVP
R-Len

32
Q

What are the two most common markers for INDOLENT mantle cell lymphoma?

A

SOX11 negative
IGHV mutated

33
Q

2L options for fit patients with FL (4)

A

BR or BO (unless prior benda)
RCHOP, OCHOP
RCVP, OCVP
R-Len

34
Q

3L or subsequent lines for R/R FL (7)

A

Epcoritamab
Mosunetuzumab
Tazemetostat
Axi-cel
Tisa-cel
Liso-cel
Zanu+Obin

35
Q

Two CAR-T products approved for R/R Mantle Cell?

A

Liso-cel
Brexucabtagene autoleucel

36
Q

Which BTKi is approved with Obinutuzumab for the treatment of R/R FL?

A

Zanubrutinib